Kidney transplant breakthrough: could this be the end of lifelong pills?
NCT ID NCT03504241
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new approach to help kidney transplant recipients stop taking anti-rejection drugs. Eight adults received donor stem cells along with a special mix of medications to see if their bodies would accept the new kidney without needing lifelong drugs. The goal was to safely reduce and possibly eliminate all anti-rejection medicine, but long-term success was not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Health System
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- Which nerve block offers better pain relief for kidney donors?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- AI may spot hidden kidney transplant rejection